Pirlimycin

This classification denotes a lincosamide antibiotic with the molecular formula C17H31ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LM19JT6G5K, chemically known as l-threo-alpha-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((4-ethyl-2-piperidinyl)carbonyl)amino)-1-thio-, monohydrochloride, (2s-cis)- but generally known as pirlimycin, which bears US NIH Compound Identifier 115329. European Medicines Agency schedules Pirlimycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09922MIG. The term PIRLIMYCIN is an International Non-Proprietary Name. PIRLIMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pirlimycin under HS 29419000 and SITC 54139. As of Q4 2014, PIRLIMYCIN remains the US FDA Preferred Term for this commodity. Pirlimycin bears US NLM identifiers UMLS ID C0071142 and NCI Concept Code C84066. SMILES: ClC(C(NC(=O)C1NCCC(C1)CC)C1OC(SC)C(O)C(O)C1O)C.Cl.